Re: Chicharros USA - bolsa internacional
Buenas tardes.....
A vueltas con las OTC....
Entré otra vez en DMPI, tras la new del congreso del fin de semana, a 1,26...
Good Morning,
Please find attached the press release DelMar Pharmaceuticals issued Friday announcing that it presented data on the benefit of VAL-083 (dianhydrogalactitol) in combination with platinum-based chemotherapy regimens in the treatment of non-small cell lung cancer (NSCLC).
The data demonstrate that VAL-083 retains activity in chemo-resistant NSCLC tumor types, which makes it a viable treatment option for NSCLC patients who fail to respond to standard-of-care platinum-based therapy or tyrosine kinase inhibitor (TKI) therapy.
Additionally, VAL-083 demonstrates a super-additive effect in NSCLC when used in combination with platinum-based chemotherapeutic agents, which supports the potential therapeutic benefit of a VAL-083 along with platinum combination regimens in newly diagnosed patients.
The Company presented results on the potential of VAL-083 in NSCLC from a collaborative study with MD Anderson Cancer Center, Shanghai Chest Hospital, and the BC Cancer Agency in a poster entitled, "Dianhydrogalactitol (VAL-083) enhances activity of platinum drugs in non-small cell lung cancer," at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
DelMar continues to build a significant portfolio of data demonstrating the activity of VAL-083 against a range of tumors, independent of their p53 status. These data taken together with the historical clinical activity support the potential of VAL-083 in NSCLC. As an important next step, the Company plans to initiate new clinical studies to validate the clinical activity of VAL-083 in patients with relapsed or refractory NSCLC who currently have a lack of treatment options and poor prognosis.
También reentro en TPIV y en LLBO a 0,73 y a 0,0034....
Sigo manteniendo ARRY, AGEN y THLD...
Veamos si entre todas cierro la semana bien...
Un saludo
